Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ANI Pharmaceuticals Inc ANIP

Healthcare
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel... see more

Recent & Breaking News (NDAQ:ANIP)

ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets

Business Wire April 11, 2022

ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors

Business Wire March 22, 2022

ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth

Business Wire March 15, 2022

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

Business Wire March 7, 2022

ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team

Business Wire February 24, 2022

Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® (betaine anhydrous for oral solution) Powder, Including 180 Days of Exclusivity

PR Newswire February 14, 2022

ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin(TM) Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders

Business Wire January 24, 2022

ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference

Business Wire January 3, 2022

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP

Business Wire December 21, 2021

Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)

GlobeNewswire December 20, 2021

ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses

Business Wire November 22, 2021

ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021

Business Wire November 22, 2021

ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma

Business Wire November 11, 2021

ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock

Business Wire November 8, 2021

ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock

Business Wire November 3, 2021

ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Business Wire November 3, 2021

ANI Pharmaceuticals Reports Third Quarter 2021 Results

Business Wire November 1, 2021

ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin(TM) Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome

Business Wire November 1, 2021

ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021

Business Wire October 29, 2021

ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021

Business Wire September 20, 2021